WO2004030607A3 - Peptide-based passive immunization therapy for treatment of atherosclerosis - Google Patents

Peptide-based passive immunization therapy for treatment of atherosclerosis Download PDF

Info

Publication number
WO2004030607A3
WO2004030607A3 PCT/SE2003/001547 SE0301547W WO2004030607A3 WO 2004030607 A3 WO2004030607 A3 WO 2004030607A3 SE 0301547 W SE0301547 W SE 0301547W WO 2004030607 A3 WO2004030607 A3 WO 2004030607A3
Authority
WO
WIPO (PCT)
Prior art keywords
passive immunization
atherosclerosis
treatment
peptide
immunization therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2003/001547
Other languages
French (fr)
Other versions
WO2004030607A2 (en
Inventor
Jan Nilsson
Roland Carlsson
Jenny Bengtsson
Leif Strandberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forskarpatent I SYD AB
Original Assignee
Forskarpatent I SYD AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0202959A external-priority patent/SE0202959D0/en
Priority claimed from SE0302312A external-priority patent/SE0302312D0/en
Priority to AT03748843T priority Critical patent/ATE498407T1/en
Priority to CA002500895A priority patent/CA2500895A1/en
Priority to DE60336068T priority patent/DE60336068D1/en
Priority to EP03748843A priority patent/EP1545609B1/en
Priority to DK03748843.4T priority patent/DK1545609T3/en
Priority to SI200331982T priority patent/SI1545609T1/en
Priority to HK06107155.0A priority patent/HK1087018B/en
Priority to BR0315042-9A priority patent/BR0315042A/en
Application filed by Forskarpatent I SYD AB filed Critical Forskarpatent I SYD AB
Priority to EEP200500012A priority patent/EE200500012A/en
Priority to JP2005500961A priority patent/JP2006506450A/en
Priority to AU2003267905A priority patent/AU2003267905B2/en
Priority to CN200380104103.2A priority patent/CN1717251B/en
Priority to ES03748843T priority patent/ES2387423T3/en
Publication of WO2004030607A2 publication Critical patent/WO2004030607A2/en
Publication of WO2004030607A3 publication Critical patent/WO2004030607A3/en
Anticipated expiration legal-status Critical
Priority to AU2009201260A priority patent/AU2009201260B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical of prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.
PCT/SE2003/001547 2002-10-04 2003-10-06 Peptide-based passive immunization therapy for treatment of atherosclerosis Ceased WO2004030607A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CN200380104103.2A CN1717251B (en) 2002-10-04 2003-10-06 Peptide-based passive immunization therapy for the treatment of atherosclerosis
ES03748843T ES2387423T3 (en) 2002-10-04 2003-10-06 DIRECTED ANTIBODIES AGAINST OXIDATED APOLIPROTEIN B
EEP200500012A EE200500012A (en) 2002-10-04 2003-10-06 Peptide-based passive immunotherapy for the treatment of atherosclerosis
DE60336068T DE60336068D1 (en) 2002-10-04 2003-10-06 Antibodies directed against oxidized apolipoprotein B
EP03748843A EP1545609B1 (en) 2002-10-04 2003-10-06 Antibodies directed against oxidised apolipoprotein B
DK03748843.4T DK1545609T3 (en) 2002-10-04 2003-10-06 Antibodies directed to oxidized apolipoprotein B
SI200331982T SI1545609T1 (en) 2002-10-04 2003-10-06 Antibodies directed against oxidised apolipoprotein B
HK06107155.0A HK1087018B (en) 2002-10-04 2003-10-06 Peptide-based passive immunization therapy for treatment of atherosclerosis
BR0315042-9A BR0315042A (en) 2002-10-04 2003-10-06 Therapy for the treatment of atherosclerosis based on passive peptide immunization
AT03748843T ATE498407T1 (en) 2002-10-04 2003-10-06 ANTIBODIES DIRECTED AGAINST OXIDATED APOLIPOPROTEIN B
CA002500895A CA2500895A1 (en) 2002-10-04 2003-10-06 Peptide-based passive immunization therapy for treatment of atherosclerosis
JP2005500961A JP2006506450A (en) 2002-10-04 2003-10-06 Peptide-based passive immunotherapy for the treatment of atherosclerosis
AU2003267905A AU2003267905B2 (en) 2002-10-04 2003-10-06 Peptide-based passive immunization therapy for treatment of atherosclerosis
AU2009201260A AU2009201260B2 (en) 2002-10-04 2009-03-31 Peptide-based passive immunization therapy for treatment of atherosclerosis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SE0202959-3 2002-10-04
SE0202959A SE0202959D0 (en) 2002-10-04 2002-10-04 Peptide-Base passive immunization therapy for the treatment of atherosclerosis
SE0302312A SE0302312D0 (en) 2002-10-04 2003-08-27 Peptide-based passive immunization therapy for the treatment of atherosclerosis
SE0302312-4 2003-08-27
SEPCT/SE03/01469 2003-09-22
PCT/SE2003/001469 WO2004030698A1 (en) 2002-10-04 2003-09-22 Peptide-based passive immunization therapy for treatment of atherosclerosis

Publications (2)

Publication Number Publication Date
WO2004030607A2 WO2004030607A2 (en) 2004-04-15
WO2004030607A3 true WO2004030607A3 (en) 2004-06-24

Family

ID=32074178

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2003/001547 Ceased WO2004030607A2 (en) 2002-10-04 2003-10-06 Peptide-based passive immunization therapy for treatment of atherosclerosis

Country Status (3)

Country Link
AU (1) AU2003267905B2 (en)
CA (1) CA2500895A1 (en)
WO (1) WO2004030607A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US10034940B2 (en) 2003-04-04 2018-07-31 Genentech, Inc. High concentration antibody and protein formulations

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0517878D0 (en) 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
WO2008104194A1 (en) * 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
PE20120359A1 (en) * 2009-03-06 2012-04-13 Genentech Inc FORMULATION WITH ANTIBODY
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
JP7722989B2 (en) 2019-11-12 2025-08-13 アブセントラ，エルエルシー Methods and compositions for treating cancer

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0433088A1 (en) * 1989-12-15 1991-06-19 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
US5494791A (en) * 1992-06-26 1996-02-27 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
WO1998042751A1 (en) * 1997-03-20 1998-10-01 University Of Leicester Oxidised fragments of apolipoprotein b and their use
US5861276A (en) * 1995-11-02 1999-01-19 Korea Institute Of Science & Technology CDNAS encoding murine antibody against human plasma apolipoprotein B-100
WO1999008109A2 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US5972890A (en) * 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
WO2001032070A2 (en) * 1999-10-26 2001-05-10 The Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
WO2001064008A2 (en) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccine for the treatment of artherosclerosis
WO2002080954A1 (en) * 2001-04-05 2002-10-17 Forskarpatent I Syd Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972890A (en) * 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
EP0433088A1 (en) * 1989-12-15 1991-06-19 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
US5494791A (en) * 1992-06-26 1996-02-27 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
US5861276A (en) * 1995-11-02 1999-01-19 Korea Institute Of Science & Technology CDNAS encoding murine antibody against human plasma apolipoprotein B-100
WO1998042751A1 (en) * 1997-03-20 1998-10-01 University Of Leicester Oxidised fragments of apolipoprotein b and their use
WO1999008109A2 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
WO2001032070A2 (en) * 1999-10-26 2001-05-10 The Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
WO2001064008A2 (en) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccine for the treatment of artherosclerosis
WO2002080954A1 (en) * 2001-04-05 2002-10-17 Forskarpatent I Syd Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US10166293B2 (en) 2000-10-12 2019-01-01 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US10034940B2 (en) 2003-04-04 2018-07-31 Genentech, Inc. High concentration antibody and protein formulations

Also Published As

Publication number Publication date
AU2003267905A1 (en) 2004-04-23
WO2004030607A2 (en) 2004-04-15
CA2500895A1 (en) 2004-04-15
AU2003267905B2 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
CY1112229T1 (en) DIRECTIONS GUIDED AGAINST OXIDATED SELF-PROTEIN B
EP1918300A3 (en) Peptide-based immunization therapy for treatment of atherosclerosis
DK1385864T3 (en) Anti-VEGF-2 antibodies
HUP9802212A2 (en) Recombinant anti-cd4 antibodies for human therapy
WO2004068931A3 (en) Amphiregulin antibodies and their use to treat cancer and psoriasis
WO2003016467A3 (en) Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
EP2298811B8 (en) Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors
WO2005047331A3 (en) Antibodies that bind interleukin-4 receptor
WO2002083849A3 (en) Vascular endothelial growth factor 2
WO2004018649A3 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
PL374383A1 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
NO20045354L (en) Methods for the treatment of angiogenesis, tumor growth and metastasis
WO2003013537A3 (en) Irinotecan for treatment of cancer
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2002060954A8 (en) Materials and methods for treatment of hepatitis c
IL159153A0 (en) Methods for testing drugs for treating or preventing diseases such as hyperlipidemia
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2003053352A3 (en) Therapeutic compounds for treating dyslipidemic conditions
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
SE0202959D0 (en) Peptide-Base passive immunization therapy for the treatment of atherosclerosis
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
ATE314066T1 (en) USE OF BUPRENORPHINE FOR THE TREATMENT OF URINARY INCONTINENCE
WO2006002195A3 (en) Method of complexing a protein by the use of a dispersed system and proteins thereof
WO2000043028A3 (en) Method of treating chronic cardiac disease
AU2002342858A1 (en) Human high-affinity antibody fragments for essential proteins of the hepatitis-c virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 167699

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2500895

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005500961

Country of ref document: JP

Ref document number: 376964

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 2003267905

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003748843

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1807/DELNP/2005

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005113235

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 20038A41032

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003748843

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 195708

Country of ref document: IL